You are here

Article info

Article menu
XML
Psoriatic arthritis
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

Authors

  1. Correspondence to Dr Philip J Mease, Rheumatology, Swedish Medical Center, Seattle WA 98122, USA; pmease{at}philipmease.com
View Full Text

Citation

Mease PJ, Lertratanakul A, Anderson JK, et al
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Annals of the Rheumatic Diseases 2021;80:312-320.

Publication history

  • Received August 13, 2020
  • Revised September 22, 2020
  • Accepted October 12, 2020
  • First published December 3, 2020.
Online issue publication 
February 11, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.